Logo
x

Search

Subscribe Now

Option to Acquire

Gilead Holds an Exclusive Option to Acquire Pionyr Immunotherapeutics for ~$1.75B

Gilead Holds an Exclusive Option to Acquire Pionyr Immunotherapeutics for ~$1.75B

  • June 24, 2020
Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

  • February 26, 2020
Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M

Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M

  • February 27, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.